Business

In today's episode of The Psychedelic Investor, James Hallifax interviews Dr. Ben Sessa of Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a psychedelic medicines company. Follow us on Twitter: @Psy_Invest @psy_holy @PsycSpotlight Follow us on Instagram: @thepsychedelicinvestor @psycspotlight To learn more about the emerging psychedelic industry, visit: https://psychedelicspotlight.com/ Dr. Ben Sessa is the Chief Medical Officer of Awakn and a well-known scientist in the psychedelics field. In this conversation, Awakn's newest clinical trial is discussed. The phase 2 trial treated Alcohol Use Disorder using ketamine-assisted therapy, and the results were amazing. For example, by the end of the trial, 86% of participants remained abstinent from alcohol. From this trial, it is clear that psychedelic therapy, or in this case ketamine therapy, can help with treating addiction. Perhaps the implications of the study go further. Perhaps, psychedelics can treat mental health issues in general. Perhaps, ketamine can be used to heal. In the conversation, MDMA to treat addiction was also discussed. Interestingly, Dr. Ben Sessa may be the only person in the world who has LEGALLY taken MDMA, psilocybin, LSD and Ketamine. With mental health care in the spotlight, and we so obviously have a mental health crisis, psychedelic medicines are seeming more likely to be the answer. From an investment perspective, psychedelic stocks are looking like they could be the next big thing. While there is no guarantee that Awakn will ultimately be a winner, their psychedelic research is definitely a boon for all psychedelic stocks. #Psychedelics #Awakn #PsychedelicStocks